Pasireotide in the Personalized Treatment of Acromegaly

Pasireotide in the Personalized Treatment of Acromegaly

The delay in controlling the disease in patients who do not respond to first-line treatment with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified in years, as every modification in the medical therapy requires some months to be fully evaluated. Considering thi...

Full description

Bibliographic Details
Main Authors: Manel Puig-Domingo, Ignacio Bernabéu, Antonio Picó, Betina Biagetti, Joan Gil, Cristina Alvarez-Escolá, Mireia Jordà, Montserrat Marques-Pamies, Berta Soldevila, María-Angeles Gálvez, Rosa Cámara, Javier Aller, Cristina Lamas, Mónica Marazuela
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Endocrinology
Subjects:
resistance to medical treatment in acromegaly
somatostatin analogues
somatostatin receptor ligands
personalized medicine
somatotroph adenoma
growth hormone
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.648411/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.648411/full

Similar Items